Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Alterity Therapeutics ( (AU:ATH) ) just unveiled an announcement.
Alterity Therapeutics Limited announced the cessation of Brian Meltzer as a director, effective November 21, 2025. This change in leadership involves Meltzer’s interests in a significant number of securities, including fully paid ordinary shares and various options, which may impact the company’s governance and strategic direction.
More about Alterity Therapeutics
Alterity Therapeutics Limited operates in the biotechnology industry, focusing on developing therapies for neurodegenerative diseases. The company is known for its work on innovative treatments aimed at addressing unmet needs in neurological health.
Average Trading Volume: 14,994,693
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$97.88M
For a thorough assessment of ATH stock, go to TipRanks’ Stock Analysis page.